Related Experiment Videos

Combination immunotherapy for advanced lung cancer

S C Yang1, E A Grimm, J A Roth

  • 1Department of General Surgery, University of Texas Health Science Center, Houston.

Journal of the National Cancer Institute. Monographs
|January 1, 1992
PubMed

Insights

This study explored using low-dose interleukin 2 with other biologic agents to activate the immune system in advanced non-small-cell lung cancer (NSCLC) patients. These immunotherapeutic strategies offer potential new treatment options for NSCLC.

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Cytokine-based therapies are under-investigated for advanced non-small-cell lung cancer (NSCLC).
  • Activating the endogenous immune system is a key goal in cancer treatment.
  • Biological agents offer potential for immunotherapeutic manipulation.

Purpose of the Study:

  • To investigate effective immunotherapeutic strategies for advanced NSCLC.
  • To explore the use of low-dose interleukin 2 (IL-2) in combination with other biologic agents.
  • To activate the host's immune system against NSCLC.

Main Methods:

  • Development of a basic laboratory and clinical research program.
  • Utilizing low-dose interleukin 2 (IL-2).
  • Administering other biologic response modifiers in conjunction with IL-2.

Main Results:

  • Summarizes research efforts in applying these immunotherapeutic manipulations.
  • Focuses on the combination of low-dose IL-2 and biologic response modifiers.
  • Highlights the investigation into activating endogenous immunity for NSCLC treatment.

Conclusions:

  • Low-dose interleukin 2 combined with biologic response modifiers represents a potential therapeutic avenue for advanced NSCLC.
  • Further research into immunotherapeutic manipulations is warranted for NSCLC.
  • Activating the endogenous immune system is a promising strategy for treating non-small-cell lung cancer.

Related Concept Videos